Protagonist Therapeutics Stock Math Transform Price Ceiling Movement
| PTGX Stock | USD 92.36 -3.06 -3.21% |
| Symbol |
Transformation |
The output start index for this execution was zero with a total number of output elements of sixty-one. Protagonist Therapeutics Price Ceiling Movement function is a real number to the largest previous price integer.
Protagonist Therapeutics Technical Analysis Modules
Most technical analysis of Protagonist Therapeutics help investors determine whether a current trend will continue and, if not, when it will shift. We provide a combination of tools to recognize potential entry and exit points for Protagonist from various momentum indicators to cycle indicators. When you analyze Protagonist charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Stock Overview, Methodology & Data Sources
Protagonist Therapeutics is scheduled to announce its earnings this week.Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California. Protagonist Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 127 people. The profile for Protagonist Therapeutics integrates fundamentals, price behavior, and sector exposure. Historical patterns suggest somewhat reduced sensitivity to broader economic swings. Protagonist Therapeutics has a market cap of 6.09 B, ROE of -20.18%.
Methodology
Unless otherwise specified, financial data for Protagonist Therapeutics is derived from periodic company reporting (annual and quarterly where available). Asset-level metrics are computed daily by Macroaxis LLC and refreshed regularly based on asset type. Protagonist (USA Stocks:PTGX) prices are typically delayed by approximately 20 minutes from primary exchanges for listed equities. Data may be delayed depending on reporting sources and market conventions. Assumptions: The dataset for Protagonist Therapeutics incorporates public filings and market reference sources and official institutional disclosures, including U.S. Securities and Exchange Commission (SEC) via EDGAR and the U.S. Patent & Trademark Office (USPTO). Some inputs may not update instantaneously. All analytics are generated using standardized, rules-based models designed to promote consistency and comparability across instruments. Model assumptions, reference parameters, and selected computational inputs are available in the Model Inputs section. If you have questions about our data sources or methodology, please contact Macroaxis Support.
Analyst Sources
Protagonist Therapeutics may have analyst coverage included in Macroaxis-derived consensus inputs when available. Updates may occur throughout the day.
This content is curated and reviewed by:
Rifka Kats - Member of Macroaxis Editorial BoardSome investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Protagonist Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Protagonist Therapeutics' short interest history, or implied volatility extrapolated from Protagonist Therapeutics options trading.
Trending Themes
If you are a self-driven investor, you will appreciate our idea-generating investing themes. Our themes help you align your investments inspirations with your core values and are essential building blocks of your portfolios. A typical investing theme is an unweighted collection of up to 20 funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of equities with common characteristics such as industry and growth potential, volatility, or market segment. | SRI Sustainable Growth Invested few shares | |
 | FinTech Invested over 20 shares | |
 | Macroaxis Index Invested over 60 shares | |
 | Investor Favorites Invested few shares | |
 | Social Domain Invested few shares | |
 | Hedge Favorites Invested few shares | |
 | Data Storage Invested few shares | |
 | Impulse Invested over 200 shares | |
 | Artificial Intelligence Invested few shares | |
 | Adviser Favorites Invested few shares |
More Resources for Protagonist Stock Analysis
A structured review of Protagonist Therapeutics often starts with core financial statements and trend context. Ratios and trend metrics help frame Protagonist Therapeutics' operating context. Key reports that frame Protagonist Therapeutics Stock are listed below:Protagonist Therapeutics has a market cap of 6.09 B, operating margin of -6.77%, ROE of -20.18%. Use Your Equity Center to explore allocation context. This includes a position in Protagonist Therapeutics in the portfolio view. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in census. To learn how to invest in Protagonist Stock, please use our How to Invest in Protagonist Therapeutics guide.Analysis related to Protagonist Therapeutics should be read together with other portfolio and risk tools before capital is reallocated. That is especially important when the goal is to improve the overall mix of instruments already held. You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
Quarterly Earnings Growth 3.513 | Earnings Share -2.05 | Revenue Per Share | Quarterly Revenue Growth -0.96 | Return On Assets |
The market value of Protagonist Therapeutics is measured differently than book value, which reflects Protagonist accounting equity. Protagonist Therapeutics' market capitalization is 6.09 B. With a P/B ratio of 9.91, the market values Protagonist Therapeutics well above its book equity. Enterprise value stands at 5.54 B. Value and price for Protagonist Therapeutics are related but not identical, and they can diverge across cycles. Trading price represents the transaction level agreed by market participants.
Note that Protagonist Therapeutics' intrinsic value and market price are different measures derived from different inputs. For Protagonist Therapeutics, key inputs include a P/B ratio of 9.91, a profit margin of -2.83%, ROE of -20.18%, and revenue of 46.02 M. Market price reflects the current exchange level formed by active bids and offers.